Novavax (NVAX) Misses Q1 EPS by 13c; Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Novavax Reports First Quarter 2022 Financial Results and Operational Highlights
May 9, 2022 4:02 PM EDTAchieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage companyReiterating full year 2022 total revenue guidance of between $4 and $5 billionContinued label expansion including primary, booster and adolescent authorizations and new shipments of Nuvaxovid into European Union, Canada, South Korea, Australia Thailand, Singapore and New Zealand Submitted request for EUA to U.S. FDA for NVX-CoV2373, with FDA Advisory Committee meeting scheduled for June 7th Announced positive Phase 1/2 results of COVID-19-Influenza Combination vaccine candidate confirming... More
